| L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways 2019 · Arm B · Colorectal cancer patients receiving FOLFOX-6 chemotherapy; ages and sex not reported | 500 mg | 90 days | 34 |
| Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure 2015 · oral orodispersible L-carnosine · Adults with stable chronic heart failure and severe left-ventricular systolic dysfunction | 500 mg | 26 weeks | 25 |
| Carnosine treatment for gulf war illness: a randomized controlled trial 2013 · carnosine · Adults with Gulf War illness or chronic fatigue syndrome diagnosed after Persian Gulf deployment; mean age among completers 51.8 years; men and women | 500 mg | 12 weeks | 19 |
| Effects of l-Carnosine Supplementation on Sleep Disorders and Disease Severity in Autistic Children: A Randomized, Controlled Clinical Trial 2018 · carnosine group · Autistic children aged 4 to 16 years, boys and girls | 500 mg | 60 days | — |
| Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial 2025 · Carnosine · Healthy adults aged 23–65 years, men and women | 1 g | 11 weeks | 153 |
| Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders 2002 · L-carnosine · Children with autistic spectrum disorders; age range and sex not stated | 800 mg | 8 weeks | — |
| l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · l-carnosine · Children aged 4–12 years with autism spectrum disorder and an ABC-C irritability subscale score of at least 12 | 800 mg | 10 weeks | — |
| l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2018 · l-carnosine plus methylphenidate · Children and adolescents aged 6–17 years with attention-deficit/hyperactivity disorder | 800 mg | 8 weeks | — |
| L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial 2020 · L-Carnosine group · Patients with major depressive disorder (DSM-V) and HAM-D score ≥19; age and sex not specified | 800 mg | 6 weeks | — |
| Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4 2019 · Active group · Adults aged 49–86 with mild cognitive impairment; both sexes | 250 mg | 12 weeks | 25 |
| A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia 2012 · L-carnosine group · Adults with chronic schizophrenia | 2 g | 90 days | — |
| L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial 2018 · l-carnosine · Patients with chronic schizophrenia, clinically stable on a stable dose of risperidone | 2 g | 8 weeks | — |
| The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial 2018 · carnosine · Pediatric patients with type 1 diabetes and diabetic nephropathy | 1 g | 12 weeks | 45 |
| Acute carnosine and β-alanine supplementation increase the compensated part of the ventilation versus work rate relationship during a ramp incremental cycle test in physically active men 2021 · Carn-βA · Healthy, physically active men; mean age 22.2 years | 2.5 g | 1 day | 10 |
| A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial 2024 · experimental formula · Adults aged 55–85 with sarcopenia | 250 mg | 120 days | 30 |
| Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases 2023 · Arm 1 or Group 1 (control group) · Children aged 3–18 years, male and female, with autism spectrum disorder | 500 mg | 90 days | 6 |
| Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial 2021 · Group 1 (carnosine) · Adults aged 18 years or older with type 2 diabetes and diabetic nephropathy | 1 g | 12 weeks | 20 |
| Anserine/Carnosine Supplementation Suppresses the Expression of the Inflammatory Chemokine CCL24 in Peripheral Blood Mononuclear Cells from Elderly People 2017 · ACS group · Healthy adults aged 41–78 years | 1 g | 90 days | — |
| Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial 2024 · carnosine supplementation group · Adults aged 23–65 years, both sexes, selected from the lowest urinary carnosine levels; otherwise healthy volunteers | 2 g | 12 weeks | — |
| Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial 2016 · carnosine · Adults with overweight or obesity, age 43 ± 8 years, without diabetes | 2 g | 12 weeks | 15 |
| Influence of l-carnosine on pro-antioxidant status in elite kayakers and canoeists 2014 · Carnosine · Male elite kayakers and canoeists | 4 g | 2 weeks | 14 |
| Carnosine supplementation reduces plasma soluble transferrin receptor in healthy overweight or obese individuals: a pilot randomised trial 2019 · Carnosine group · Otherwise healthy overweight or obese middle-aged adults | 2 g | 12 weeks | 14 |
| Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial 2017 · Carnosine group · Healthy, non-diabetic overweight and obese adults; mean age 43 ± 7 years overall | 2 g | 12 weeks | 13 |
| Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese Otherwise Healthy Adults: A Pilot Randomized Trial 2018 · carnosine group · Overweight or obese, sedentary, non-diabetic adults who were otherwise healthy | 2 g | 12 weeks | 13 |
| Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial 2024 · carnosine · Adults with prediabetes or type 2 diabetes; age range not stated; 30% of the trial population were female | 2 g | 14 weeks | — |
| A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial 2015 · Dietary supplement (Glycabiane) · Adults aged 25–65 years, overweight or obese, with pre-diabetes/impaired fasting glucose | 200 mg | 120 days | 26 |
| Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases 2023 · Arm 2 or Group 2 (Nichi Glucan group) · Children aged 3–18 years, male and female, with autism spectrum disorder | 500 mg | 90 days | 11 |
| Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study 2018 · supplement group · Obese adults with type 2 diabetes mellitus | 6 mg/kg | 8 weeks | — |
| A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients 2016 · food supplement containing α-lipoic acid · Caucasian adults aged 18–75 years, both sexes, with overweight and type 2 diabetes and HbA1c >7.0% | 165 mg | 90 days | 54 |